Efficacy on symptoms and mortality day vs. night administration of EGFR-TKIs for advanced non-small cell lung cancer
Supportive Care in Cancer · 2024
DOI: 10.1007/s00520-024-08839-y ↗Kurz gefasst
Fachartikel in der Zeitschrift Supportive Care in Cancer, 2024. Verfasst von Onam Ok und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nursing, Graduate School of Clinical Nursing Science, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Protein Kinase Inhibitors, ErbB Receptors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 21 Literaturangaben. Gefördert von: Institution of Quality of Life in Cancer funded by Samsung Fire & Marine Insurance.
Abstract (Originalsprache)
PURPOSE: This study has a purpose to investigate the side effects of three EGFR-TKIs targeted therapeutic agents (gefitinib, erlotinib, and afatinib) and all-cause mortality in patients with metastatic lung cancer. METHODS: We performed a prospective cohort study. We selected all patients with newly diagnosed metastatic lung cancer between January and November 2019. Main exposure was daytime versus nighttime use of targeted EGFR TKIs. The study outcome was a symptom change using the mobile application, and all-cause mortality between January 2019 and March 2023. RESULTS: Among the 87 study participants, 35 (40%) took their medication at night. Among the 87 study participants, 35 (40%) took their medication at night. At 6 weeks of treatment, acne (1.36; 95% confidence interval [CI] 1.09, 1.64; p for interaction = 0.04) and dry skin (1.35; 95% CI 1.09, 1.61, p for interaction = 0.01) in the day group showed a much increase from baseline compared to the night group. In contrast, the night group reported greater reductions in lung cancer-related symptoms from baseline compared to the day. During follow-up (median 43 months), the night group had a lower risk of all-cause death than the day group, especially in younger patients (adjusted hazard ratio = 0.34; 95% CI 0.13, 0.87). CONCLUSIONS: The group taking EGFR-TKIs at night experienced fewer side effects and had longer overall survival compared to the day group. Clinicians should consider recommending that lung cancer patients take their once-daily oral anticancer drugs in the evening rather than the morning to improve treatment outcomes.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Nursing, Graduate School of Clinical Nursing Science, Samsung Medical Center, Sungkyunkwan University, Seoul, Republic of Korea.
- Department of Clinical Research Design and Evaluation, SAIHST, Sungkyunkwan University, Seoul, Republic of Korea.
- Center for Clinical Epidemiology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Cancer Education Center, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Department of Radiation Oncology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
Förderung
- Institution of Quality of Life in Cancer funded by Samsung Fire & Marine Insurance
Zitieren
APA
Ok, O., Lee, M., Kim, N., Cho, J., Hong, S. Y., Nam, M. S., Yi, M. S., Oh, D., Ahn, J. S., Kang, D., & Hong, J. H. (2024). Efficacy on symptoms and mortality day vs. night administration of EGFR-TKIs for advanced non-small cell lung cancer. Supportive Care in Cancer. https://doi.org/10.1007/s00520-024-08839-y
Vancouver
Ok O, Lee M, Kim N, Cho J, Hong SY, Nam MS, et al. Efficacy on symptoms and mortality day vs. night administration of EGFR-TKIs for advanced non-small cell lung cancer. Supportive Care in Cancer. 2024. doi:10.1007/s00520-024-08839-y
BibTeX
@article{Ok2024,
author = {Ok, Onam and Lee, Mangyeong and Kim, Nayeon and Cho, Juhee and Hong, Sun Young and Nam, Min Sun and Yi, Mi Sun and Oh, Dongryul and Ahn, Jin Seok and Kang, Danbee and Hong, Jeong Hee},
title = {Efficacy on symptoms and mortality day vs. night administration of EGFR-TKIs for advanced non-small cell lung cancer},
journal = {Supportive Care in Cancer},
year = {2024},
doi = {10.1007/s00520-024-08839-y}
}
EUVIMED